TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.

导出 OA

翻译打印收藏纠错

第一作者： Myrofora,Panagi

第一单位： Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus.

作者： Myrofora,Panagi ^[1] ; Chrysovalantis,Voutouri ^[1] ; Fotios,Mpekris ^[1] ; Panagiotis,Papageorgis ^[1] ; Margaret R,Martin ^[2] ; John D,Martin ^[3] ; Philippos,Demetriou ^[3] ; Chryso,Pierides ^[4] ; Christiana,Polydorou ^[4] ; Andreas,Stylianou ^[1] ; Maria,Louca ^[1] ; Laura,Koumas ^[1] ; Paul,Costeas ^[4] ; Kazunori,Kataoka ^[5] ; Horacio,Cabral ^[4] ; Triantafyllos,Stylianopoulos ^[5]

作者单位： Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus. ^[1] Department of Life Sciences, Program in Biological Sciences, European University Cyprus, Nicosia, Cyprus. ^[2] Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, Japan. ^[3] The Center for the Study of Haematological Malignancies, Nicosia, Cyprus. ^[4] Karaiskakio Foundation, Nicosia, Cyprus. ^[5] Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa, Japan. ^[6] Institute of Future Initiatives, The University of Tokyo, Bunkyo, Tokyo, Japan. ^[7]

关键词 immunostimulation immunotherapy nanomedicine normalization tumor microenvironment vascular perfusion